TEIJINHuman Chemistry, Human Solutions

Teijin Pharma Limited GLOBAL

  • Site Map
  • Contact Us
  • Enlarge Text

menu

  • About Us
  • Our Business Structure
  • Site Map
  • Contact Us

About Us:TOP

  • Corporate Philosophy
  • Message from the President
  • Group Synergies
  • Office Locations
  • Alliance Partners
  • History
  • Corporate Social Responsibility
  • Project Stories
  • News

Our Business Structure:TOP

Business Fields
  • About Teijin Pharma
Business Activities
  • Research & Development
  • Industrial Technology
  • Regulatory Compliance

  • Japan Local Site日本

Home > News Release

News Release

Latest News Release

RSS

Jun. 03, 2025
  • Navepegritide Designated as an Orphan Drug by Japan’s Ministry of Health, Labor and Welfare
Dec. 13, 2024
  • Teijin Pharma Limited Applies for Manufacturing and Marketing Approval in Japan for New Hypoparathyroidism Treatment
Apr. 10, 2024
  • Teijin Pharma Grants Global Exclusive License to Bioprojet to Develop a New Orexin Receptor 2 Agonist Investigational Candidate for Narcolepsy
Feb. 13, 2024
  • Teijin and Axcelead to Determine the Name of Drug Discovery Research JV
Nov. 29, 2023
  • Notice Concerning a Decision on the Licensing Agreement related to the Three Hormone Therapy Drugs for Rare Endocrine Diseases
Jul. 03, 2023
  • Teijin and Axcelead to Establish Drug Discovery Research Joint Venture
Mar. 06, 2023
  • Teijin Pharma Grants Global Exclusive Licens for Investigational Small Molecule Candidate in Kidney Disease
Apr. 05, 2022
  • Iktos and Teijin Pharma to Co-Develop New Technology for Small Molecule Drug Discovery
Feb. 01, 2022
  • Anti-Tau Antibody created by Teijin Pharma and developed by Merck & Co., Inc., Kenilworth NJ USA Enters Clinical Development
Jun. 23, 2021
  • Teijin Receives Additional Approval in Japan for Merz’s Xeomin® Botulinum Toxin Type A

Page Top


News Release

  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • Notice

We use cookies to help improve your experience on our website. Clink on "Agree" to agree and proceed, or click on "See Details" for more information and settings of cookies.

See Details
  • Terms & Conditions of Use
  • Privacy Policy

Copyright © Teijin Pharma Limited. All Rights Reserved.